Outpatient management of fever in neutropenic patients

Current Opinion in Infectious Diseases

Volumn 9, Issue 6, 1996, Pages 407-410

  Rolston, Kenneth V I ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT;

COST CONTROL; FEVER; HEALTH CARE COST; HIGH RISK PATIENT; HUMAN; NEUTROPENIA; OUTPATIENT; PATIENT SATISFACTION; QUALITY OF LIFE; RESOURCE MANAGEMENT; RISK ASSESSMENT; SHORT SURVEY;

EID: 0030444533     PISSN: 09517375     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001432-199612000-00009     Document Type: Short Survey

References (15)

1. Bodey GP, Buckley M, Sathe YS, Freireich EJ: Quantitative relationships between circulating leucocytes and infections in patients with acute leukaemia. Ann Intern Med 1966, 64:328-340.
2. Hughes WT, Armstrong D, Bodey GP, Feld R, Mandell GL, Meyers JD, Pizzo PA, Schimpff SC, Scenep JL, Wade JC et al. (Working Committee, Infectious Disease Society of America): Guidelines for the use of antimicrobial agents in neutropenic patients with unexplained fever. J Infect Dis 1990, 1612:381-396.
3. Talcott JA, Finberg R, Mayer RJ, Goldman L: The medical course of cancer patients with fever and neutropenia. Clinical identification of a low-risk subgroup at presentation. Arch Intern Med 1988, 148:2561-2568.
4. Talcott JA, Siegel RD, Finberg R, Goldman L: Risk assessment in cancer patients with fever and neutropenia; a prospective, two-center validation of a prediction rule. J Clin Oncol 1992, 10:316-322.
5. Rubin M, Hathorn JW, Pizzo PA: Controversies in the management of febrile neutropenic cancer patients. Cancer Invest 1988, 6:267-282.
6. Lucas KG, Brown AE, Armstrong D, Chapman D, Heller G: The identification of febrile, neutropenic children with neoplastic disease at low risk for bacteremia and complications of sepsis. Cancer 1996, 77:791-798. Identification of low-risk groups in children with cancer who develop fever while neutropenic.
7. Haron E, Rolston KVI, Cunningham C, Holmes F, Umsawasdi T, Bodey GP: Oral ciprofloxacin therapy for infections in cancer patients. J Antimicrob Chemother 1989, 24:955-962.
8. Malik LA, Abbas Z, Karim M: Randomized comparison of oral ofloxacin alone with combination of parenteral antibiotics in neutropenic febrile patients. Lancet 1992, 339:1092-1096.
9. Talcott JA, Whalen A, Clark J, Rieker PP, Finberg R: Home antibiotic therapy for low-risk cancer patients with fever and neutropenia: a pilot study of 30 patients based on a validated prediction rule. J Clin Oncol 1994, 12:107-114.
10. Malik IA, Khan WA, Aziz Z, Karim M: Self-administered antibiotic therapy for chemotherapy-induced, low-risk febrile neutropenia in patients with non-hematologic neoplasms. Clin Infect Dis 1994, 19:522-527
11. Malik IA, Khan WA, Karim M, Aziz Z, Khan MA: Feasibility of outpatient management of fever in cancer patients with low-risk neutropenia: results of a prospective randomized trial. Am J Med 1995, 98:224-231. Randomized trial of inpatient versus outpatient antibiotic therapy showed no differences in outcome, although 25% assigned to outpatient therapy required subsequent hospitalization.
12. Rubenstein EB, Rolston K, Benjamin RS, Loewy J, Escalante E, Manzullo E, Hughes P, Moreland B, Fender A, Kennedy K et al.: Outpatient treatment of febrile episodes in low-risk neutropenic patients with cancer. Cancer 1993, 71:3640-3646.
13. Rolston KVI, Rubenstein EB, Elting L, Escalante C, Manzullo E et al.: Ambulatory management of febrile episodes in low-risk neutropenic patient Abstract 2235, Programs and Abstracts of the 35th Interscience Conference of Antimicrobial Agents and Chemotherapy. San Francisco, CA Washington DC: Am Soc Microbiology (ASM); 1995; 33.
14. Rolston KVI, Rubenstein EB, Freifeld A: Early empiric antibiotics for febrile neutropenia patients at low risk. Infect Dis Clin North Am 1996, 10:223-237.
15. Gilbert C, Meisenberg B, Vredenburgh J, Ross M, Hussein A, Perfect J, Peters WP: Sequential prophylactic oral and empiric once-daily parenteral antibiotics for neutropenia and fever after high-dose chemotherapy and autologous bone marrow support. J Clin Oncol 1994, 12:1005-1011.